Characteristics of Patients With Inflammatory Bowel Disease Who Develop Bloodstream Infection

被引:1
|
作者
Kamada, Mitsuhiro [1 ]
Miyazaki, Motoyasu [1 ]
Nakashima, Akio [1 ]
Yamada, Yota [1 ]
Nakano, Takafumi [2 ]
Hagiwara, Daiki [2 ]
Komiya, Yukie [3 ]
Matsuo, Koichi [1 ]
Imakyure, Osamu [1 ]
机构
[1] Fukuoka Univ, Dept Pharm, Chikushi Hosp, Fukuoka 8188502, Japan
[2] Fukuoka Univ Hosp, Dept Pharm, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Chikushi Hosp, Dept Clin Lab, Fukuoka 8188502, Japan
来源
关键词
Crohn's disease; Ulcerative colitis; Bloodstream infection; PSEUDOMONAS-AERUGINOSA; DIVERSITY;
D O I
10.14740/jocmr4920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The causative microorganisms of bloodstream infec-tions (BSIs) in patients with inflammatory bowel disease (IBD) and the clinical characteristics of these patients have not yet been fully identified. Therefore, this study investigated IBD patients who devel-oped BSI to determine their clinical characteristics and identify the BSI-causing bacteria. Methods: The subjects were IBD patients who developed bactere-mia between 2015 and 2019 at Fukuoka University Chikushi Hos-pital. The patients were divided into two groups according to IBD type (Crohn's disease (CD) or ulcerative colitis (UC)). The medical records of the patients were reviewed to determine their clinical back-grounds and identify the BSI-causing bacteria. Results: In total 95 patients, 68 CD and 27 UC patients were included in this study. The detection rates of Pseudomonas aeruginosa (P. aer-uginosa) and Klebsiella pneumoniae (K. pneumoniae) were higher in the UC group than in the CD group (18.5% vs. 2.9%, P = 0.021; 11.1% vs. 0%, P = 0.019, respectively). Immunosuppressive drugs use was higher in the CD group than in the UC group (57.4% vs. 11.1%, P = 0.00003). Hospital stay length was longer in the UC group than in the CD group (15 vs. 9 days; P = 0.045). Conclusions: The causative bacteria of BSI and clinical backgrounds differed between patients with CD and UC. This study showed that P. aeruginosa and K. pneumoniae had higher abundance in UC patients at the onset of BSI. Furthermore, long-term hospitalized patients with UC required antimicrobial therapy against P. aeruginosa and K. pneumoniae.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 50 条
  • [21] Opportunistic Infection in Hospitalised Patients with Inflammatory Bowel Disease
    Zhou, Jin-Qiu
    Meng, Zhang-Min
    Zhang, Tao
    Jing, Xing-Tao
    Gan, Hua-Tian
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (10): : 1015 - 1020
  • [22] Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease
    Joshi, N. M.
    Rampton, D. S.
    PRACTICAL GASTROENTEROLOGY, 2012, 36 (11) : 16 - +
  • [23] Evaluation of Cytomegalovirus Infection in Patients With Inflammatory Bowel Disease
    Carmo, Alexandre M.
    Santos, Fabiana M.
    Ortiz-Agostinho, Carmen Lucia
    Nishitokukado, Ieda
    Frota, Cintia S.
    Gomes, Flavia U.
    Leite, Andr Z.
    Pannuti, Claudio S.
    Teixeira, Magaly G.
    Sipahi, Aytan M.
    GASTROENTEROLOGY, 2013, 144 (05) : S627 - S627
  • [24] Prevalence of cytomegalovirus infection in inflammatory bowel disease patients
    Takahashi, Y
    Tange, T
    DISEASES OF THE COLON & RECTUM, 2004, 47 (05) : 722 - 726
  • [26] Clostridium difficile Infection in Patients with Inflammatory Bowel Disease
    Nancy Fu
    Titus Wong
    Current Infectious Disease Reports, 2016, 18
  • [27] Cytomegalovirus infection in patients with active inflammatory bowel disease
    Alain, S
    Ducancelle, A
    Le Pors, NJS
    Mazeron, MC
    de Saussure, P
    Bouhnik, Y
    Lavergne, A
    JOURNAL OF CLINICAL VIROLOGY, 2005, 33 (02) : 180 - 182
  • [28] Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease
    John J. Kim
    Nicole Simpson
    Nancy Klipfel
    Renee DeBose
    Nancy Barr
    Loren Laine
    Digestive Diseases and Sciences, 2010, 55 : 1059 - 1065
  • [29] Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
    Albarrak, Abdulmajeed A.
    Romana, Bhupinder S.
    Uraz, Suleyman
    Yousef, Mohamad H.
    Juboori, Alhareth A.
    Tahan, Veysel
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2019, 19 (07) : 929 - 935
  • [30] Does Inflammatory Bowel Disease Develop in Infants?
    Kappelman, Michael D.
    Grand, Richard J.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 : S6 - S8